ArticlemAbs
Antitumor effects of a monoclonal antibody to human CCR9 in leukemia cell xenografts.
Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- The role of chemokines and interleukins in acute lymphoblastic leukemia: a systematic review.Journal of applied biomedicine · 2024Pooled it
- Enhancing Magnetic Hyperthermia at the Cell Membrane by Anchoring 92R-Functionalized Magnetic Nanoparticles to Low-Endocytic CCR9 Surface Receptors.Advanced healthcare materials · 2026Article
- Signal termination of the chemokine receptor CCR9 is governed by an arrestin-independent phosphorylation mechanism.The Journal of biological chemistry · 2025Article
- Discovery of Therapeutic Antibodies Targeting Complex Multi-Spanning Membrane Proteins.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2024Review
- Review
- Identification of the Binding Epitope of an Anti-Mouse CCR6 Monoclonal Antibody (CAntibodies (Basel, Switzerland) · 2023Article
- Determination of the Binding Epitope of an Anti-Mouse CCR9 Monoclonal Antibody (CAntibodies (Basel, Switzerland) · 2023Article
- Therapeutic potential of an anti-CCR9 mAb evidenced in xenografts of human CCR9Frontiers in immunology · 2022Article
- Chemokine Receptor Antagonists: Role in Oncology.Current oncology reports · 2021Review
- Targeting chemokines for acute lymphoblastic leukemia therapy.Journal of hematology & oncology · 2021Review
- CCL25 Signaling in the Tumor Microenvironment.Advances in experimental medicine and biology · 2021Article
- CCR9 Promotes Migration and Invasion of Lung Adenocarcinoma Cancer Stem Cells.International journal of medical sciences · 2020Article
- The role of chemokine receptor 9/chemokine ligand 25 signaling: From immune cells to cancer cells.Oncology letters · 2018Review
- 92R Monoclonal Antibody Inhibits Human CCR9Frontiers in immunology · 2018Article
- Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets.Frontiers in immunology · 2017Review
- CCR9 in cancer: oncogenic role and therapeutic targeting.Journal of hematology & oncology · 2016Review
- CCR9-CCL25 interaction suppresses apoptosis of lung cancer cells by activating the PI3K/Akt pathway.Medical oncology (Northwood, London, England) · 2015Article
- Chemokine receptor-specific antibodies in cancer immunotherapy: achievements and challenges.Frontiers in immunology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor expression of certain chemokine receptors is associated with resistance to apoptosis, migration, invasiveness and metastasis. Because CCR9 chemokine receptor expression is very restricted in healthy tissue, whereas it is present in tumors of distinct origins including leukemias, melanomas, prostate and ovary carcinomas, it can be considered a suitable candidate for target-directed therapy. Here, we report the generation and characterization of 91R, a mouse anti-human CCR9 IgG2b monoclonal antibody that recognizes an epitope within the CCR9 N-terminal domain. This antibody inhibits the growth of subcutaneous xenografts from human acute T lymphoblastic leukemia MOLT-4 cells in immunodeficient Rag2(-/-) mice. Tumor size in 91R-treated mice was reduced by 85% compared with isotype-matched antibody-treated controls. Tumor reduction in 91R-treated mice was concomitant with an increase in the apoptotic cell fraction and tumor necrotic areas, as well as a decrease in the fraction of proliferating cells and in tumor vascularization. In the presence of complement or murine natural killer cells, 91R promoted in vitro lysis of MOLT-4 leukemia cells, indicating that this antibody might eliminate tumor cells via complement- and cell-dependent cytotoxicity. The results show the potential of the 91R monoclonal antibody as a therapeutic agent for treatment of CCR9-expressing tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.